Engage in the discovery and development of biopharmaceutical products. Manufacture and market small molecule drugs and biologics. Now — the numbers.
Revenue is spread across several lines; no single product carries the company.
This is an established company with proven profits.
Average growth of 19% a year over the last 4 years. Every year shown ended in profit.
The gap is $15.5B. In times of high interest rates, a gap like that can squeeze a company.
The stock trades 50% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 26% — that slice of every sale is the company’s cushion in hard quarters.
Over the last 4 years, sales grew about 19% a year on average.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
The stock sits at $0.10. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.